IRIS Institutional Research Information System - OPENBS Open Archive UniBS

PECORELLI, Sergio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.427
EU - Europa 3.641
AS - Asia 1.919
AF - Africa 21
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 9
SA - Sud America 9
Totale 17.042
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.378
CN - Cina 1.391
UA - Ucraina 1.288
IT - Italia 568
DE - Germania 516
PL - Polonia 394
FI - Finlandia 331
HK - Hong Kong 330
IE - Irlanda 192
GB - Regno Unito 153
IN - India 103
FR - Francia 95
SE - Svezia 57
CA - Canada 44
TR - Turchia 24
SG - Singapore 20
MU - Mauritius 18
NL - Olanda 18
EU - Europa 16
VN - Vietnam 16
BE - Belgio 13
AU - Australia 9
IR - Iran 9
BR - Brasile 6
TW - Taiwan 4
BG - Bulgaria 3
CH - Svizzera 3
ID - Indonesia 3
KR - Corea 3
MX - Messico 3
RU - Federazione Russa 3
CL - Cile 2
JP - Giappone 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LU - Lussemburgo 2
SA - Arabia Saudita 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BO - Bolivia 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
EE - Estonia 1
ES - Italia 1
MA - Marocco 1
MS - Montserrat 1
NG - Nigeria 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
Totale 17.042
Salva come PNG Salva come JPEG
Città #
Fairfield 1.662
Woodbridge 1.636
Houston 1.108
Jacksonville 914
Ashburn 897
Ann Arbor 800
Wilmington 761
Seattle 695
Cambridge 642
Warsaw 393
Chandler 364
Nanjing 353
Princeton 353
Hong Kong 312
New York 218
Dearborn 212
Dublin 192
Beijing 180
Helsinki 147
Nanchang 128
San Diego 90
Shenyang 87
Des Moines 86
Changsha 67
Hebei 67
Kunming 66
Milan 59
Jiaxing 58
Jinan 55
Shanghai 49
Tianjin 48
Toronto 43
Hangzhou 41
Brescia 39
Los Angeles 28
Ningbo 25
London 23
Verona 22
Zhengzhou 22
Monmouth Junction 20
Lancaster 18
Lanzhou 18
Taizhou 18
Rome 17
Washington 17
Dong Ket 16
Hefei 16
Norwalk 16
Orange 16
Pune 16
Central 14
San Francisco 14
Brussels 13
Taiyuan 12
Fuzhou 10
Ardabil 9
Guangzhou 9
Haikou 9
Kocaeli 9
Leawood 8
Kilburn 7
New Bedfont 7
San Mateo 7
Changchun 6
Falkenstein 6
Melbourne 6
Amsterdam 5
Chicago 5
Dalmine 5
Augusta 4
Boardman 4
Hanover 4
Indiana 4
Lappeenranta 4
Prezzo 4
São Paulo 4
Trani 4
Arezzo 3
Auburn Hills 3
Bologna 3
Chiari 3
Frankfurt am Main 3
Mexico City 3
North 3
Phoenix 3
Sofia 3
Taoyuan District 3
Wuhan 3
Acton 2
Almaty 2
Baotou 2
Baton Rouge 2
Bergamo 2
Berlin 2
Bishkek 2
Cheongju-si 2
Chongqing 2
Colombo 2
Florence 2
Fort Worth 2
Totale 13.380
Salva come PNG Salva come JPEG
Nome #
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. 256
Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection in adolescents in Northern Italy: an observational school-based study. 254
Bambini pretermine: nati per vivere 252
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Zhao S1, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD 239
Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery 218
OVEREXPRESSION OF CLOSTRIDIUM PERFRINGENS ENTEROTOXIN RECEPTORS CLAUDIN-3 AND CLAUDIN-4 IN UTERINE CARCINOSARCOMAS. 181
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. 147
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone 142
Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. 141
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition 140
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma 135
Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). 135
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. 134
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes 132
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients 132
Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women 131
Consolidation therapies revisited: weekly paclitaxel 129
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. 128
An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin 128
Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. 127
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. 125
Identification of optimal reference genes for gene expression normalization in a wide cohort of endometrioid endometrial carcinoma tissues. 125
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. 124
Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum 124
Carcinoma of the Fallopian tube 124
HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas 123
Overexpression of mammaglobin B in epithelial ovarian carcinomas. 121
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. 119
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence 118
Trefoil factor 3: a novel serum marker identified by gene expression profiling in highgrade endometrial carcinomas 116
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). 114
Basic fibroblast growth factor in ovulatory cycle and postmenopausal human endometrium. 114
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma 113
Mental health and the global agenda. 113
Chlamydia trachomatis genotypes in school adolescents, Italy 113
Strategies to Improve Medication Adherence in Older Persons: Consensus Statement from the Senior Italia Federanziani Advisory Board 113
Mammaglobin B expression in human endometrial cancer 112
ADVANCES IN DENDRITIC-CELL-BASED THERAPEUTIC VACCINES FOR CERVICAL CANCER. 111
Replacement therapy for breast cancer survivors. A pilot study 111
Histological features of uteroplacental vessels in normal and hypertensive patients in relation to birthweight 110
Gestational trophoblastic diseases 110
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis 110
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. 108
DEVELOPMENT AND THERAPEUTIC EFFECT OF ADOPTIVELY TRANSFERRED T CELLS PRIMED BY TUMOR LYSATE-PULSED AUTOLOGOUS DENDRITIC CELLS IN A PATIENT WITH METASTATIC ENDOMETRIAL CANCER. 108
TUMOR-INFILTRATING LYMPHOCYTES CONTAIN HIGHER NUMBERS OF TYPE 1 CYTOKINE EXPRESSORS AND DR+ T CELLS COMPARED WITH LYMPHOCYTES FROM TUMOR DRAINING LYMPH NODES AND PERIPHERAL BLOOD IN PATIENTS WITH CANCER OF THE UTERINE CERVIX. 108
Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. 108
MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities. 108
Revised FIGO staging for carcinoma of the vulva, cervix, andendometrium. 107
High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody 107
Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody 107
Toward appropriate criteria in medication adherence assessment in older persons: Position Paper 106
Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. 105
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. 105
Carcinoma of the Fallopian tube 105
HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. 104
Advanced Age and Medication Prescription: More Years, Less Medications? A Nationwide Report From the Italian Medicines Agency 104
Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference 104
Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer 102
IN VITRO INDUCTION OF TUMOR-SPECIFIC HUMAN LYMPHOCYTE ANTIGEN CLASS I-RESTRICTED CD8 CYTOTOXIC T LYMPHOCYTES BY OVARIAN TUMOR ANTIGEN-PULSED AUTOLOGOUS DENDRITIC CELLS FROM PATIENTS WITH ADVANCED OVARIAN CANCER. 102
Prescription drug use among older adults in Italy: A country-wide perspective 102
INDUCTION OF OVARIAN TUMOR-SPECIFIC CD CYTOTOXIC T LYMPHOCYTES BY ACID-ELUTED PEPTIDE-PULSED AUTOLOGOUS DENDRITIC CELLS 101
Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer 101
High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian Medicines Agency (AIFA) 101
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor 101
Computational and functional analysis of biopharmaceutical drugs in zebrafish: Erythropoietin as a test model 101
History of the FIGO cancer staging system 100
Time to face the challenge of multimorbidity. A European perspective from the joint action on chronic diseases and promoting healthy ageing across the life cycle (JA-CHRODIS) 100
Scaling up health knowledge at European level requires sharing integrated data: An approach for collection of database specification 100
Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. 99
Early stage cervical cancer: adjuvant treatment in negative lymph node cases. 99
New development of the FIGO staging system. 98
Staging classification for cancer of the ovary, fallopian tube, and peritoneum 98
Which second-line treatment regimen should be used following relapse of platinum-sensitive ovarian cancer? 97
Systemic therapy for gynecological neoplasms: ovary, cervix, and endometrium. 97
Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium 97
INCREASED LEVELS OF INTERLEUKIN-10 AND TRANSFORMING GROWTH FACTOR-BETA IN THE PLASMA AND ASCITIC FLUID OF PATIENTS WITH ADVANCED OVARIAN CANCER. 96
Racial differences in overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in Uterine Serous Papillary Cancer 96
Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. 95
hI-con1, a factor VII-IgGFc chimeric protein targetingtissue factor for immunotherapy of uterine serous papillary carcinoma. 95
High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. 95
Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor 95
Neoadjuvant chemotherapy in the treatment of locally advanced cervical carcinoma in pregnancy 94
Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcomas cell lines is linked to tubulin-beta-III expression. 94
Early stage ovarian cancer: the Italian contribution to clinical research. An update 94
Hormone replacement therapy in breast cancer 94
Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody 93
Hearing loss and cognitive decline in older adults: Questions and answers 93
Interval debulking surgery in advanced epithelial ovarian cancer 93
Optimizing gemcitabine regimens in ovarian cancer. 92
Revised FIGO staging for carcinoma of the cervix. 92
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) 92
Gestational trophoblastic diseases 92
The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in squamous cervicalcancer cells. 90
Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8-9, 2007. 89
THE NOVEL SERINE PROTEASE TUMOR-ASSOCIATED DIFFERENTIALLY EXPRESSED GENE-14 (KLK8/NEUROPSIN/OVASIN) IS HIGHLY OVEREXPRESSED IN CERVICAL CANCER. 89
Interval Cytoreduction in Ovarian Cancer 88
Radiation-Enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma 88
Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer. 88
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. 88
High serum levels of interleukin-6 in endometrialcarcinoma are associated with uterine serous papillary histology, a highlyaggressive and chemotherapy-resistant variant of endometrial cancer. 88
Totale 11.537
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.274
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.274
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.051 0 0 0 0 0 0 0 0 0 0 550 501
2019/20205.136 689 153 177 653 330 744 523 547 370 566 110 274
2020/20212.785 64 363 116 345 126 334 135 323 360 263 271 85
2021/20221.537 124 236 13 71 11 106 77 88 77 292 123 319
2022/20231.190 240 30 50 69 83 343 10 94 153 11 52 55
2023/20241.313 78 35 145 108 82 358 49 60 330 57 11 0
Totale 17.482